HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031).

Abstract
The effect of Prednimustine was evaluated in 37 patients with generalised non-Hodgkin's lymphomas. The patients were divided into three groups according to dosage and previous treatment. Totally, in all three groups, 22 complete and 10 partial remissions were observed. During follow-up, five of the complete responders and all partial responders have relapsed. Leucopenia and thrombocytopenia were induced in several patients, but were always moderate and reversible after withdrawal of the drug. In some patients with a history of peptic ulcer or diabetes mellitus, these conditions were aggravated.
AuthorsL Håkansson, I Könyves, L G Lindberg, T Möller
JournalOncology (Oncology) Vol. 35 Issue 3 Pg. 103-6 ( 1978) ISSN: 0030-2414 [Print] Switzerland
PMID673314 (Publication Type: Journal Article)
Chemical References
  • Chlorambucil
  • Prednisolone
Topics
  • Adult
  • Aged
  • Chlorambucil (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Female
  • Humans
  • Leukopenia (chemically induced)
  • Lymphoma (drug therapy, pathology)
  • Male
  • Middle Aged
  • Prednisolone (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Thrombocytopenia (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: